淋巴结清扫与辅助化疗对早期卵巢癌患者生存的影响:一项全国队列研究的更新
该更新全国队列研究纳入2000至2020年荷兰FIGO 2014分期I-IIA或IIIA1期上皮性卵巢癌患者5407例,其中2911例(53.8%)行淋巴结切除。校正年龄、分期、肿瘤分级和组织学后,淋巴结清扫组十年相对生存显著优于未清扫组(83.3% vs 73.3%,RER 0.56,95%CI 0.48-0.66)。在切除10枚及以上淋巴结的患者中,接受辅助化疗者十年相对生存显著更高(RER 0.64,95%CI 0.41-1.00,p=0.048),高危亚组同样如此(RER 0.59,95%CI 0.37-0.95,p=0.028)。
要点
- 早期上皮性卵巢癌行淋巴结清扫者十年相对生存显著优于未清扫者(83.3% vs 73.3%)。
- 切除10枚及以上淋巴结并接受辅助化疗与十年相对生存改善相关(RER 0.64,95%CI 0.41-1.00)。
- 高危特征亚组接受辅助化疗同样与生存改善相关(RER 0.59,95%CI 0.37-0.95)。
核心结论
- 对于早期上皮性卵巢癌患者,切除10枚及以上淋巴结并提供辅助化疗与十年随访后相对生存改善相关。
- 辅助化疗对相对生存改善的贡献具有临床相关性,且与既往仅报告五年随访生存率的发现相反。
研究设计与样本
- 更新版全国队列研究,纳入2000年至2020年在荷兰诊断的FIGO 2014分期I-IIA或IIIA1期上皮性卵巢癌患者,共5407例。
- 数据来自荷兰癌症登记处,提取患者、肿瘤、治疗特征及生存数据。
主要发现
- 5407例患者中2911例(53.8%)行淋巴结切除。
- 淋巴结清扫组与未清扫组十年相对生存分别为83.3%和73.3%,校正年龄、分期、肿瘤分级和组织学后RER 0.56(95%CI 0.48-0.66)。
- 切除10枚及以上淋巴结的患者中,接受辅助化疗者与未接受者相比十年相对生存显著更高(RER 0.64,95%CI 0.41-1.00,p=0.048)。
- 高危特征亚组(stage IC和IIA和/或肿瘤分级3和/或透明细胞组织学)中,接受辅助化疗者十年相对生存同样显著更高(RER 0.59,95%CI 0.37-0.95,p=0.028)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine the impact of lymph node dissection and adjuvant chemotherapy on survival in patients with early-stage epithelial ovarian cancer (EOC) in an updated national cohort study. METHODS: All patients with International Federation of Gynaecology and Obstetrics (FIGO) 2014 stage I-IIA or IIIA1 EOC, diagnosed in the Netherlands between 2000 and 2020 (8 additional years) were included. Data concerning patient, tumour and treatment characteristics and survival were extracted from the Netherlands Cancer Registry. RESULTS: Of 5407 patients included, 2911 (53.8 %) had lymph nodes removed. Ten-year relative survival (RS) of patients with (compared to without) lymph node dissection was significantly better, also after correcting for age, stage, tumour grade and histology (83.3 % and 73.3 %, respectively; relative excess risk [RER] 0.56; 95 % confidence interval [CI]: 0.48-0.66). After adjusting for confounders, patients with 10+ lymph nodes removed had a significantly higher ten-year RS if they received adjuvant chemotherapy compared to those who did not (RER 0.64; 95 % CI 0.41-1.00, p = 0.048). This was also true for a subgroup of patients with high-risk features (stage IC and IIA and/or tumour grade 3 and/or clear cell histology) (RER 0.59; 95 % CI 0.37-0.95, p = 0.028). CONCLUSION: For early-stage EOC patients, removing 10 or more lymph nodes and providing adjuvant chemotherapy is associated with improved RS after 10 years of follow-up. The contribution of adjuvant chemotherapy to improved RS is clinically relevant and in contrast to our previous findings reporting survival rates after only five years of follow-up.
引用
- Laven P, Wenzel HHB, van der Aa MA, et al. Impact of lymph node dissection and adjuvant chemotherapy on survival of patients with early-stage ovarian cancer: Update of a national cohort study. Gynecol Oncol. 2025. PMID: 40695058. doi:10.1016/j.ygyno.2025.07.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。